Richmond Pharmacology helps UK patients gain early access to ultra-rare disease drug Lumasiran

Posted:
17
August 2020

Richmond Pharmacology early phase drug development update.

The Medicines and Healthcare Products Regulatory Agency (MHRA) has granted Alnylam's lumasiran a positive scientific opinion through the Early Access to Medicines Scheme (EAMS).

The decision allows patients with the ultra-rare disease primary hyperoxaluria type 1 (PH1) access to the drug before its official approval by the European Commission.

PH1 is an ultra-rare orphan disease affecting around 90 patients in the UK, that causes an abnormal build-up of toxic oxalate in the liver, resulting in painful and recurrent kidney stones and ultimately irreparable damage to the kidneys and other vital organs.

Richmond Pharmacology is proud to have been involved in the early stage of the drug and supported the development through a first-in-human combined healthy volunteer and patient trial.

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Making gains in drug development

September 2, 2021
Keith Berelowitz outlines the innovations in the design and delivery of clinical trials
Read more

Inclisirin hailed as a 'gamechanger' gains approval for NHS patients

September 2, 2021
This novel therapeutic drug has potential to impact millions at risk of heart attack and stroke.
Read more

Richmond Pharmacology listed in the Alantra Pharma Fast 50

July 13, 2021
Richmond has been included in a top 50 list of the UK’s fastest-growing, privately-owned pharmaceutical businesses. 
Read more